Hexarelin, a growth hormone - releasing peptide, counteracts bone loss in gonadectomized male rats.

Sibilia V, Cocchi D, Pagani F, Lattuada N, Moro GL, Pecile A, Rubinacci A, Muller EE, Netti C

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society1 Aug 1999Cited by 11 (Europe PMC)

PMID10512687DOI10.1054/ghir.1999.0105PepBankPUB-10512687

Publisher page PubMedAsk about this study

Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In intact rats, hexarelin decreased urinary lysylpyridinoline excretion by 36.3% at day 7.
In plain wordsIn rats with normal hormones, hexarelin lowered a bone breakdown marker at day 7.
Peptide
Hexarelin
Outcome
DecreaseLysylpyridinoline excretion in intact rats
Study
ratn: not reported in source
Intact and gonadectomized mature male rats
Comparator
Intact rats before treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
50 microg/kg twice daily · subcutaneous · 30 daysAs given in this study (rat).
Measurements
LP excretion change
−36.3%
intact rats, day 7
Source sentences
Summary
In intact rats, HEXA significantly (P<0.05) decreased LP (-36.3%) and HP (-22.8%) excretion at day 7, whereas it did not change serum ALP activity and BMDs.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of the present study was to examine the effects of 30-day treatment with hexarelin (HEXA, 50 microg/kg subcutaneously b.i.d.), a highly effective GH-releasing compound, on bone metabolism and bone mineral density (BMD) in intact and osteopenic gonadectomized (GDX) mature male rats.
Report a problemFND-1051268701
02AnimalAnimal study (in vivo)Efficacy outcome
In intact rats, hexarelin decreased urinary hydroxylysylpyridinoline excretion by 22.8% at day 7.
In plain wordsIn rats with normal hormones, hexarelin lowered a second bone breakdown marker at day 7.
Peptide
Hexarelin
Outcome
DecreaseHydroxylysylpyridinoline excretion in intact rats
Study
ratn: not reported in source
Intact and gonadectomized mature male rats
Comparator
Intact rats before treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
50 microg/kg twice daily · subcutaneous · 30 daysAs given in this study (rat).
Measurements
HP excretion change
−22.8%
intact rats, day 7
Source sentences
Summary
In intact rats, HEXA significantly (P<0.05) decreased LP (-36.3%) and HP (-22.8%) excretion at day 7, whereas it did not change serum ALP activity and BMDs.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of the present study was to examine the effects of 30-day treatment with hexarelin (HEXA, 50 microg/kg subcutaneously b.i.d.), a highly effective GH-releasing compound, on bone metabolism and bone mineral density (BMD) in intact and osteopenic gonadectomized (GDX) mature male rats.
Report a problemFND-1051268702
03AnimalAnimal study (in vivo)Efficacy outcome
In intact rats, hexarelin did not change serum alkaline phosphatase activity.
In plain wordsIn rats with normal hormones, hexarelin did not change a blood marker of bone formation.
Peptide
Hexarelin
Outcome
No significant changeSerum alkaline phosphatase in intact rats
Study
ratn: not reported in source
Intact and gonadectomized mature male rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
50 microg/kg twice daily · subcutaneous · 30 daysAs given in this study (rat).
Source sentences
Summary
In intact rats, HEXA significantly (P<0.05) decreased LP (-36.3%) and HP (-22.8%) excretion at day 7, whereas it did not change serum ALP activity and BMDs.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of the present study was to examine the effects of 30-day treatment with hexarelin (HEXA, 50 microg/kg subcutaneously b.i.d.), a highly effective GH-releasing compound, on bone metabolism and bone mineral density (BMD) in intact and osteopenic gonadectomized (GDX) mature male rats.
Report a problemFND-1051268703
04AnimalAnimal study (in vivo)Efficacy outcome
In intact rats, hexarelin did not change bone mineral density.
In plain wordsIn rats with normal hormones, hexarelin did not change bone density.
Peptide
Hexarelin
Outcome
No significant changeBone mineral density in intact rats
Study
ratn: not reported in source
Intact and gonadectomized mature male rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
50 microg/kg twice daily · subcutaneous · 30 daysAs given in this study (rat).
Source sentences
Summary
In intact rats, HEXA significantly (P<0.05) decreased LP (-36.3%) and HP (-22.8%) excretion at day 7, whereas it did not change serum ALP activity and BMDs.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of the present study was to examine the effects of 30-day treatment with hexarelin (HEXA, 50 microg/kg subcutaneously b.i.d.), a highly effective GH-releasing compound, on bone metabolism and bone mineral density (BMD) in intact and osteopenic gonadectomized (GDX) mature male rats.
Report a problemFND-1051268704
05AnimalAnimal study (in vivo)Efficacy outcome
In gonadectomized rats, hexarelin completely prevented the increase in urinary lysylpyridinoline excretion caused by androgen deficiency.
In plain wordsIn rats with the testes removed, hexarelin fully prevented a rise in a bone breakdown marker.
Peptide
Hexarelin
Outcome
DecreaseLysylpyridinoline excretion in gonadectomized rats
Study
ratn: not reported in source
Intact and gonadectomized mature male rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
50 microg/kg twice daily · subcutaneous · 30 daysAs given in this study (rat).
Source sentences
Summary
In GDX rats, HEXA completely prevented the significant (P<0. 01) increase in urinary excretion of both LP (+143.8%) and HP (+119. 4%), the early decrease in ALP activity (-26.5%) and the significant (P<0.05) decrease in BMDs in the femoral metaphysis (-7.9%) and lumbar vertebrae (-6.8%) caused by androgen deficiency.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of the present study was to examine the effects of 30-day treatment with hexarelin (HEXA, 50 microg/kg subcutaneously b.i.d.), a highly effective GH-releasing compound, on bone metabolism and bone mineral density (BMD) in intact and osteopenic gonadectomized (GDX) mature male rats.
Report a problemFND-1051268705
06AnimalAnimal study (in vivo)Efficacy outcome
In gonadectomized rats, hexarelin completely prevented the increase in urinary hydroxylysylpyridinoline excretion caused by androgen deficiency.
In plain wordsIn rats with the testes removed, hexarelin fully prevented a rise in a second bone breakdown marker.
Peptide
Hexarelin
Outcome
DecreaseHydroxylysylpyridinoline excretion in gonadectomized rats
Study
ratn: not reported in source
Intact and gonadectomized mature male rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
50 microg/kg twice daily · subcutaneous · 30 daysAs given in this study (rat).
Source sentences
Summary
In GDX rats, HEXA completely prevented the significant (P<0. 01) increase in urinary excretion of both LP (+143.8%) and HP (+119. 4%), the early decrease in ALP activity (-26.5%) and the significant (P<0.05) decrease in BMDs in the femoral metaphysis (-7.9%) and lumbar vertebrae (-6.8%) caused by androgen deficiency.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of the present study was to examine the effects of 30-day treatment with hexarelin (HEXA, 50 microg/kg subcutaneously b.i.d.), a highly effective GH-releasing compound, on bone metabolism and bone mineral density (BMD) in intact and osteopenic gonadectomized (GDX) mature male rats.
Report a problemFND-1051268706
07AnimalAnimal study (in vivo)Efficacy outcome
In gonadectomized rats, hexarelin completely prevented the early decrease in alkaline phosphatase activity caused by androgen deficiency.
In plain wordsIn rats with the testes removed, hexarelin fully prevented an early drop in a bone formation marker.
Peptide
Hexarelin
Outcome
IncreaseAlkaline phosphatase activity in gonadectomized rats
Study
ratn: not reported in source
Intact and gonadectomized mature male rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
50 microg/kg twice daily · subcutaneous · 30 daysAs given in this study (rat).
Source sentences
Summary
In GDX rats, HEXA completely prevented the significant (P<0. 01) increase in urinary excretion of both LP (+143.8%) and HP (+119. 4%), the early decrease in ALP activity (-26.5%) and the significant (P<0.05) decrease in BMDs in the femoral metaphysis (-7.9%) and lumbar vertebrae (-6.8%) caused by androgen deficiency.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of the present study was to examine the effects of 30-day treatment with hexarelin (HEXA, 50 microg/kg subcutaneously b.i.d.), a highly effective GH-releasing compound, on bone metabolism and bone mineral density (BMD) in intact and osteopenic gonadectomized (GDX) mature male rats.
Report a problemFND-1051268707
08AnimalAnimal study (in vivo)Efficacy outcome
In gonadectomized rats, hexarelin completely prevented the decrease in bone mineral density in the femoral metaphysis caused by androgen deficiency.
In plain wordsIn rats with the testes removed, hexarelin fully prevented loss of bone density in the thigh bone.
Peptide
Hexarelin
Outcome
IncreaseFemoral metaphysis bone mineral density in gonadectomized rats
Study
ratn: not reported in source
Intact and gonadectomized mature male rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
50 microg/kg twice daily · subcutaneous · 30 daysAs given in this study (rat).
Source sentences
Summary
In GDX rats, HEXA completely prevented the significant (P<0. 01) increase in urinary excretion of both LP (+143.8%) and HP (+119. 4%), the early decrease in ALP activity (-26.5%) and the significant (P<0.05) decrease in BMDs in the femoral metaphysis (-7.9%) and lumbar vertebrae (-6.8%) caused by androgen deficiency.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of the present study was to examine the effects of 30-day treatment with hexarelin (HEXA, 50 microg/kg subcutaneously b.i.d.), a highly effective GH-releasing compound, on bone metabolism and bone mineral density (BMD) in intact and osteopenic gonadectomized (GDX) mature male rats.
Report a problemFND-1051268708
09AnimalAnimal study (in vivo)Efficacy outcome
In gonadectomized rats, hexarelin completely prevented the decrease in bone mineral density in the lumbar vertebrae caused by androgen deficiency.
In plain wordsIn rats with the testes removed, hexarelin fully prevented loss of bone density in the lower spine.
Peptide
Hexarelin
Outcome
IncreaseLumbar vertebrae bone mineral density in gonadectomized rats
Study
ratn: not reported in source
Intact and gonadectomized mature male rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
50 microg/kg twice daily · subcutaneous · 30 daysAs given in this study (rat).
Source sentences
Summary
In GDX rats, HEXA completely prevented the significant (P<0. 01) increase in urinary excretion of both LP (+143.8%) and HP (+119. 4%), the early decrease in ALP activity (-26.5%) and the significant (P<0.05) decrease in BMDs in the femoral metaphysis (-7.9%) and lumbar vertebrae (-6.8%) caused by androgen deficiency.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of the present study was to examine the effects of 30-day treatment with hexarelin (HEXA, 50 microg/kg subcutaneously b.i.d.), a highly effective GH-releasing compound, on bone metabolism and bone mineral density (BMD) in intact and osteopenic gonadectomized (GDX) mature male rats.
Report a problemFND-1051268709
10AnimalAnimal study (in vivo)Mechanism
In rats treated chronically with hexarelin, the GH response to an acute hexarelin challenge was maintained.
In plain wordsIn rats given hexarelin for 30 days, the growth hormone response to a new hexarelin dose stayed intact.
Peptide
Hexarelin
Outcome
No significant changeGH response to acute hexarelin after chronic treatment
Study
ratn: not reported in source
Intact and gonadectomized mature male rats
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
50 microg/kg twice daily · subcutaneous · 30 daysAs given in this study (rat).
Source sentences
Summary
The bone-protective effects of HEXA could be attributed, at least in part, to its GH-releasing activity since chronic-treated rats maintained the GH response to an acute challenge with HEXA.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of the present study was to examine the effects of 30-day treatment with hexarelin (HEXA, 50 microg/kg subcutaneously b.i.d.), a highly effective GH-releasing compound, on bone metabolism and bone mineral density (BMD) in intact and osteopenic gonadectomized (GDX) mature male rats.
Report a problemFND-1051268710

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.